OncoMatch/Clinical Trials/NCT06679816

Hydrocortisone in Hormone Replacement Therapy for Large Pituitary Neuroendocrine Tumors

Is NCT06679816 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies Hormone replacement therapy for pituitary adenoma.

Treatment: Hormone replacement therapy — The goal of this clinical trial is to assess the need for hydrocortisone replacement therapy during the perioperative period for large pituitary neuroendocrine tumors. The main questions it aims to answer are: • Does hydrocortisone replacement therapy reduce the incidence of adrenal insufficiency in participants? Researchers will compare hydrocortisone to a placebo (a look-alike substance that contains no drug) to see if hydrocortisone works to reduce the incidence of adrenal insufficiency. Participants will: * Take or intravenous infusion drug hydrocortisone or a placebo every day for 2 weeks * Visit the clinic three months after surgery for checkups and tests * Keep a diary of their symptoms